Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 12/20 | 0.33 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
| ▸ | CA6 | P23280 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14458460 | 0.90 | IMPDH2 (0.33) | IMPDH2IMPDH1CA1CA2CA4 | |
| SCHEMBL5145143 | 0.88 | — | — | |
| SCHEMBL10748647 | 0.87 | CA1 (0.31) | IMPDH2CA1CA2CA4CA6 | |
| SCHEMBL5086099 | 0.85 | CA1 (0.30) | CA1CA2CA4CA6 | |
| SCHEMBL8924397 | 0.82 | IMPDH2 (0.40) | IMPDH2IMPDH1 | |
| SCHEMBL11425051 | 0.79 | IMPDH2 (0.33) | IMPDH2 | |
| SCHEMBL15071874 | 0.79 | CA2 (0.42) | IMPDH2IMPDH1CA1CA2CA4 | |
| SCHEMBL14459544 | 0.76 | IMPDH2 (0.34) | IMPDH2 | |
| SCHEMBL12640817 | 0.76 | — | — | |
| SCHEMBL3044602 | 0.75 | IMPDH2 (0.31) | IMPDH2IMPDH1CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220055975-A1 | REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS | PTC THERAPEUTICS, INC. | 2022-02-24 | — | — | US | disclosed |
| US-11021424-B2 | Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | PTC THERAPEUTICS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| EP-1933821-B1 | TAIL VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS | PTC THERAPEUTICS INC (US) | 2020-07-29 | — | — | EP | disclosed |
| EP-1933821-B1 | TAIL VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS | PTC THERAPEUTICS INC (US) | 2020-07-29 | — | — | EP | disclosed |
| EP-2564843-B1 | Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | BIOELECTRON TECH CORP (US) | 2018-12-26 | — | — | EP | disclosed |
| EP-2332534-B1 | Phenol and benzoquinone derivatives for use in the treatment of mitochondrial diseases and modulation of energy biomarkers | BIOELECTRON TECH CORP (US) | 2018-11-14 | — | — | EP | disclosed |
| US-9932286-B2 | Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | BIOELECTRON TECHNOLOGY CORPORATION (US) | 2018-04-03 | — | — | US | disclosed |
| US-9932286-B2 | Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | BIOELECTRON TECHNOLOGY CORPORATION (US) | 2018-04-03 | — | — | US | disclosed |
| US-9932286-B2 | Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | BIOELECTRON TECHNOLOGY CORPORATION (US) | 2018-04-03 | — | — | US | disclosed |
| EP-2617418-B1 | PHENOL AND 1,4-BENZOQUINONE DERIVATIVES FOR USE IN THE TREATMENT OF MITOCHONDRIAL DISEASES | BIOELECTRON TECH CORP (US) | 2017-11-22 | — | — | EP | disclosed |
| WO-2007035496-A1 | TAIL VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS | EDISON PHARMACEUTICALS, INC. (US) | 2007-03-29 | — | — | WO | disclosed |
| US-20060281809-A1 | Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | PTC THERAPEUTICS, INC. | 2006-12-14 | — | — | US | disclosed |
| WO-2006130775-A2 | REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMAKERS | EDISON PHARMACEUTICALS, INC. (US) | 2006-12-07 | — | — | WO | disclosed |
| US-5624961-A | Benzylaminoethoxybenzene derivatives, production thereof and use thereof | JAPAN TOBACCO INC. (JP) | 1997-04-29 | — | — | US | disclosed |
| EP-0693474-A1 | NOVEL BENZYLAMINOETHOXYBENZENE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE THEREOF | Toyo Boseki Kabushiki Kaisha (JP) | 1996-01-24 | — | — | EP | disclosed |
| CN-1114644-A | Novel benzylaminoethoxybenzene derivatives, production thereof and use thereof | TOYO BOSEKI (JP) | 1996-01-10 | — | — | CN | disclosed |
| US-5110955-A | Chiral rhodium or palladium-diphosphine catalyst | HOFFMANN-LA ROCHE INC. (US) | 1992-05-05 | — | — | US | disclosed |
| US-4234490-A | Intermediates in the synthesis of vitamin E | HOFFMANN-LA ROCHE INC. (US) | 1980-11-18 | — | — | US | disclosed |
| US-4201879-A | Hydroquinones | HOFFMANN-LA ROCHE INC. (US) | 1980-05-06 | — | — | US | disclosed |
| US-4153614-A | Synthesis of (S)-(+)-6-hydroxy-2,5,7,8-tetramethylchroman-2-methanol and intermediates therein | HOFFMANN-LA ROCHE INC. (US) | 1979-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281809-A1 | Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | ECHS1, FH, ACAA2 | IMPDH2 3688/4885IMPDH1 3441/4885CA1 2709/4885 |
| US-11021424-B2 | Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | ECHS1, FH, ACAA2 | IMPDH2 3688/4885IMPDH1 3441/4885CA1 2709/4885 |
| US-20220055975-A1 | REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS | ECHS1, FH, ACAA2 | IMPDH2 3688/4885IMPDH1 3441/4885CA1 2709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.